The Beauty of a Competitor's Misfortune
Let’s be clear. Getting a drug approved for a rare, or ‘orphan’, disease is a brutal, eye-wateringly expensive affair. You face the same punishing regulatory gauntlet as a company developing a blockbuster for millions, but your target market might be a few thousand people scattered across the globe. When a would-be competitor spends a decade and hundreds of millions of pounds only to fail at the final hurdle, it does more than just remove a rival from the field. It reinforces the enormous walls protecting the companies already inside the castle.
To me, this is the crux of the matter. Companies like Ultragenyx Pharmaceutical have built their entire empires on this principle. They operate in niche markets where competition is, by its very nature, scarce. Each successful drug they get to market is like a tiny, protected monopoly. The recent failure of a potential competitor doesn't just maintain the status quo, it actively strengthens their position, making their existing revenue streams look even more secure.
